Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.00%
)
US TECH 100
28,298.40
(
-1.71%
)
Dow Jones
50,063.46
(
0.00%
)
Brent Oil
105.49
(
1.25%
)
Bitcoin
80,138.34
(
-1.13%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 162078

Monday, 06/03/2013 6:40:03 PM

Monday, June 03, 2013 6:40:03 PM

Post# of 257566
PTLA—There’s nothing wrong with Betrixaban per se, but it’s not differentiated from Eliquis (or Xarelto) and it’s very late to market even in the best-case scenario. That’s why MRK pulled out of the partnership to develop Betrixaban two years ago (#msg-61300408).

If PTLA would scrap Betrixaban and focus only on extracting maximum value for PRT-4445, I would be more inclined to invest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today